Advertisement

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Varsha Gandhi, PhD, on Ibrutinib

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement




Feb
26
Today In Oncology
Intravesical Immunotherapy Shows Recurrence Control in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer
Gemcitabine Intravesical System Shows High Disease-Free Survival Rates in BCG-Unresponsive Papillary-Only NMIBC
FDA Approves Encorafenib for Metastatic BRAF V600E–Mutated Colorectal Cancer
MRI-Based Neoadjuvant Chemotherapy Duration in HER2-Positive Breast Cancer
Can a New Testing Method Allow More Patients With Bladder Cancer to Avoid Radical Cystectomy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo